Onkologie. 2013:7(5):256-258
Patient with metastatic breast cancer and complet response during treatment with regimen paclitaxel and bevacizumab
- Interní hematologická a onkologická klinika, FN Brno
Background: The role of the bevacizumab in the treatment metastatic breast cancer (MBC) is not clear. The studies fase III (E2100, RIBBON-
1) can declare profit for groups of patients treated with bevacizumab and standart first line of chemotherapy (high number of
responses and longer overal survival).
Case: We present the case of a patient with MBC triplet negative high grade with imperative symptomas (nauzea, anorexia, weight loss
and pain) The patient was treated with chemotherapy bevacizumab and paclitaxel within 26 months. Complet remission was declared
by CT/PET scan and first progression we detected 48 months later.
Conclusion: A good quality of life and long-term persistent complete remission (16 months) was achieved, no transfusion, no hospitalization.
Overall survival was 61 months.
Keywords: metastatic breast cancer (MBC), complete remission, bevacizumab, paclitaxel, chemotherapy
Published: November 1, 2013 Show citation
| ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
References
- Dušek L, Vyzula R, Melichar B, et al. Čiselne podklady pro planovani nakladů lečebne peče v onkologii- analyzy dostupnych populačnich dat a predikce pro rok 2013 modra kniha česke onkologicke společnosti - 16. vydani, platne od 1. 2. 2013: 220-230.
- Sochor M, Chlebus P. Antiangiogenní bioterapie a chemoterapie v terapii karcinomu prsu: přehled literatury a kazuistika Klinická onkologie, 26, 2013, 2, 91-98.
- Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist. 2011; 16(suppl 1): 1-11.
Go to original source... 
Go to PubMed...